2018
DOI: 10.5230/jgc.2018.18.e9
|View full text |Cite
|
Sign up to set email alerts
|

Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis

Abstract: PurposeIt has been reported that the survival of patients with locally advanced gastric cancer (LAGC) is better in East Asia countries than in developed western countries; however, the prognosis of LAGC remains poor. This study aimed to evaluate the effects of perioperative chemotherapy on the long-term survival of East Asia patients with LAGC.Materials and MethodsFrom October 2006 through August 2008, 43 patients with LAGC received perioperative S-1 combined with weekly docetaxel in a phase II study (neoadjuv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(11 citation statements)
references
References 29 publications
0
11
0
Order By: Relevance
“…[5][6][7] To improve patients' survival, a variety of studies have examined the treatment effect of additional chemotherapy and radiotherapy. [8][9][10] Among these, neoadjuvant chemotherapy (or perioperative chemotherapy) was first advocated by Wilke et al 11 It is now widely accepted that neoadjuvant chemotherapy (NAC) can help improve patients' tolerance, increase curative resection rate, decrease tumor metastasis, and thus increase the survival rate. [12][13][14] As a result of its increasing popularity, there is now an increasing need for practical tools to predict individual survival after NAC.…”
Section: Introductionmentioning
confidence: 99%
“…[5][6][7] To improve patients' survival, a variety of studies have examined the treatment effect of additional chemotherapy and radiotherapy. [8][9][10] Among these, neoadjuvant chemotherapy (or perioperative chemotherapy) was first advocated by Wilke et al 11 It is now widely accepted that neoadjuvant chemotherapy (NAC) can help improve patients' tolerance, increase curative resection rate, decrease tumor metastasis, and thus increase the survival rate. [12][13][14] As a result of its increasing popularity, there is now an increasing need for practical tools to predict individual survival after NAC.…”
Section: Introductionmentioning
confidence: 99%
“…The main end point of this study is PFS. According to literature, the 5-year PFS of the operation control group is about 45% [26][27][28]; we speculate that with the L-HIPEC + NAC intervention, the 5-year PFS can be increased to 60% (estimating a 15% increase). The random distribution ratio of the experimental group and the control group is 1:1, the test level α is set to 0.05 on both sides, the statistical test efficiency (power) is set to 80% (β = 0.2).…”
Section: Sample Size Calculationmentioning
confidence: 76%
“…Eastern Asia, Eastern Europe, and South America are considered as regions with a high incidence rate of gastric cancer in the world [1]. Available evidence supports the beneficial effect of perioperative chemotherapy in comparison with surgery alone on the prognosis of resectable gastric cancers [2][3][4][5]. Perioperative chemotherapy has been reported to lead to higher overall survival, progression-free survival, and curative resection rate [6,7].…”
Section: Introductionmentioning
confidence: 99%